Rekombinanter TNFSF4 (Oxelumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter TNFSF4 (Oxelumab Biosimilar) Antikörper (ABIN5564244)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Spezifität
- Recognizes human OX40L.
-
Kreuzreaktivität
- Human
-
Reinheit
- >95 % (SDS-PAGE)
-
Endotoxin-Niveau
- <0.001EU/μg
-
Immunogen
- Recombinant human OX40L.
-
Isotyp
- IgG1
-
-
-
-
Kommentare
-
This antibody is a biosimilar generically called Oxelumab (CAS 1186098-83-8) and originally developed by Genentech. Oxelumab is a OX40 ligand blocker designed for the prevention of allergen-induced airway inflammation in adults with mild asthma. Potentially other application areas are transplantation and autoimmunity research or protection against inflammation-driven fibrosis.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- Lot specific
-
Buffer
- In PBS.
-
Konservierungsmittel
- Without preservative
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C. -
Haltbarkeit
- 12 months
-
-
- TNFSF4 (Oxelumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
- OX40L is a membrane-expressed cytokine that belongs to the TNF ligand family. It acts as costimulator through interaction with its ligand OX40 on T cells, stimulating T cell activation, proliferation and cytokine production. OX40L is expressed on antigen presenting cells including B cells, dendritic cells, mast cells and endothelium.
-
UniProt
- P23510
Target
-